LUC7L3

Across TCGA pan-cancer cohorts, LUC7L3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated LUC7L3 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher LUC7L3 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated LUC7L3 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

LSCC, CCRCC, and LUAD are the cancer types where LUC7L3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Tertile	II,III,IV	0.948	0.586	.006	14	view →
CCRCC	DFS	Median	All	0.724	0.883	.022	5	view →
LUAD	OS	Quartile	II,III,IV	0.789	0.389	.026	4	view →
HNSC	DFS	Quartile	III,IV	0.860	0.973	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

LUC7L3–LSCC (OS)

Open the LSCC breakdown →